Medplus HealthQ4 FY24

Medplus Health Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹608.85P/E: 34.7Market Cap: ₹7.3K CrSector: Retailing

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • The company expects GMV (Gross Merchandising Value) growth of around 27.4% year-on-year, indicating strong volume growth.
  • In Tamil Nadu, GMV growth exceeds 16% where focused advertising has been done.
  • Private label GMV has grown significantly from 8.1% last year to 13.7% currently, supporting revenue growth.
  • Store additions are expected to continue at around 600 stores per year, with growth focus in Tier 2 cities and beyond.
  • Mature stores (24-36 months) typically grow at a same-store sales growth rate of approximately 10%, driven by pharma inflation plus category expansion.
  • The share of revenue from Tier 2 markets has increased to 35%, up from 33% last year, contributing to diversified growth.
  • The company targets improving pharmacy operating EBITDA margins alongside volume growth driven by private label expansion and operational leverage.

See what Medplus Health management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The company currently has no debt apart from timing mode of depreciation.
  • The management indicated that operating cash flows are expected to turn positive and generate surplus cash in the next 2-3 years.
  • Planned investment for store expansion is around INR 200-220 crores annually, with 600-800 stores expected to be added per year.
  • Future growth funding will primarily come from operating cash flows and leveraging working capital credit lines as needed, rather than fresh debt or equity fundraising.
  • No explicit mention of new equity or debt fundraising plans in the current fiscal or near future was provided.
  • The focus is on reaching cash flow stability and self-funding growth through operational earnings and internal accruals.

See what Medplus Health management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The company is currently in a growth phase, investing around INR 200-220 crores per year on store expansion, with about INR 25-30 lakhs invested per store.
  • They plan to add approximately 600 new stores in fiscal year 2025.
  • Capex for diagnostics within Hyderabad will involve only maintenance-type investments (e.g., ultrasound machines), with no large-scale capital expenditures planned.
  • Overall, operating cash flows are expected to remain negative during the growth phase due to ongoing investments.
  • Management expects to generate surplus operating free cash flow in 2-3 years as store base matures and EBITDA grows.
  • Future cash flow and capex needs will be managed through credit lines as necessary.
  • The focus remains on expanding the pharmacy network, especially in Tier 2 cities and beyond, with strategic investments supporting store additions and private label brand growth.

Track Medplus Health — get its next earnings analysis in your feed

How does Medplus Health rank vs peers in Retailing?

Pro feature
ThisMedplus Health
Rev 2Mar 2

How does Medplus Health rank in Retailing?

Compare Medplus Health against every Retailing company (Q4 FY24) on revenue, margins and earnings-call signals.

View Retailing leaderboard →

Others in Retailing this season

  • Acetech E-Commerce (Q2 FY27)

    Revenue from Operations for the half year ended September 30, 2026 is ₹4,055.15 lakhs (Standalone) vs ₹3,986.48 lakhs for the same period in 2025…

  • Net Avenue (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026, is ₹132,043 thousand (~₹132.04 million), compared to ₹116,869 thousand (~₹116.87 million)…

  • On Door Concepts (Q2 FY27)

    EBITDA for the quarter**: ₹824.13 lakhs . Key results statement takeaways from On Door Concepts Ltd's Q2 FY27 results statement — and how it ranks against secto

  • Brainbees Solutions (Q2 FY27)

    Consolidated revenue for Q2 FY27 was INR 23,958 Mn, growing 14.1% YoY, the strongest growth in six quarters (Pages 12, 13, 35). Key investor presentation takeaw

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →